Today's New Buy Pick - electroCore, Inc. (ECOR) – Buy Target – $1.10 or better

Sponsored Content Stocks Are Higher Even As U.S. Surgeon General Says This Week “Is Going To Be Our 9/11” Moment Amid The COVID-19 Pandemic

Monday’s bullish sentiment was driven by optimism that the spread of the coronavirus may be peaking in the U.S., even as cases rise that least 337,600 and the death toll nears 10,000. While the Trump administration acknowledged that this week could be among the toughest for hot sports like New York, the administration struck a more optimistic tone in a press conference on Sunday, noting signs that there’s stabilization in terms of hospitalization rates and other factors. ... Read More

SIGA Technologies Inc (NASDAQ: SIGA): SIGA Technologies shares are up more than 7% today following the company’s announcement that the Canadian Department of National Defense has awarded a contract to Meridian Medical Technologies Inc to purchase up to 15,325 courses of SIGA’s oral TPOXX (tecovirimat) treatment over four years for a total value of $14.3 million. “The current ... Read More

This might be the time to take MAN’s bargain status seriously There is a point where COVID-19’s immediate impact – on the health of people all over the globe, and the stress that puts on healthcare systems in every country, including the U.S. – will find a peak and begin to turn back down. That point may be weeks or months to come, and until then we have to put safety first and foremost. At the same time, it’s worth taking note of the very real impact the widespread shut down of business activity is having. Last week’s unemployment cla... Read More

Featured Stock electroCore, Inc. (ECOR) – Buy Target – $1.10 or better electroCore, Inc., a bioelectronic medicine company, engages in developing a range of patient-administered non-invasive vagus nerve (VNS) stimulation therapies for the treatment of various conditions in neurology, rheumatology, and other fields. The company is developing gammaCore, a prescription-only non-invasive VNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Read More

Other Top Stories Federal Reserve to smooth lending to small businesses Work starts in Montana on disputed Canada-US oil pipeline Cracks in Europe's shared currency reappear in virus crisis Austrian, Czech officials plan to ease some virus measures SeaWorld CEO resigns five months into job, cites board

Trend Following Picks electroCore, Inc. (ECOR) – Buy Target – $1.10 or better iFresh Inc. (IFMK) – Buy Target – $1.70 or better Citrix Systems, Inc. (CTXS) -Buy Target – $142.50 or better Clearfield, Inc. (CLFD) – Buy Target – $12.00 or better Novavax, Inc. (NVAX) – Buy Target – $14.50 or better All Picks

Reversal Picks New Concept Energy, Inc. (GBR) Buy Target $0.90 Sell Target $1.12 Clear Channel Outdoor Holdings, Inc. (CCO) Buy Target $1.41 Sell Target $2.05 Charles & Colvard, Ltd. (CTHR) Buy Target $0.98 Sell Target $1.22 Blueprint Medicines Corporation (BPMC) Buy Target $60.15 Sell Target $70.57 Extraction Oil & Gas, Inc. (XOG) Buy Target $1.12 Sell Target $1.68 All Picks

Already subscribed to our premium service? Click here to Login. Not a TradersPro subscriber yet? Learn More About TradersPro Here - Learn The # 1 Key To Successful Stock Investing Profits

---

This email was sent to its028@gmail.com by Investiv, LLC

265 N. Main | Ste. D #283 | Kaysville | UT | 84037
Forward to a friend | Unsubscribe or Mange which emails you get from TradersPro

Disclaimers

Investing is Inherently Risky

There are risks inherent in all investments, which may make such investments unsuitable for certain persons. These include, for example, economic, political, currency exchange, rate fluctuations, and limited availability of information on international securities. You may lose all of your money trading and investing. Do NOT enter any trade without fully understanding the worst-case scenarios of that trade. And do NOT trade with money you cannot afford to lose. Past performance of an investment is not necessarily indicative of its future results. No assurance can be given that any implied recommendation will be profitable or will not be subject to losses.

Hypothetical Results Are Reported

Results and examples used in the Company's advertisements, books, videos, websites, and other media—including on the Site and the Network—are, in some cases, based on hypothetical (simulated) trades. Plainly speaking, these trades were not actually executed. Hypothetical performance results have certain limitations. Unlike an actual performance record, hypothetical results do not represent actual trading. Also, since the trades have not been executed, the hypothetical results may have under-or-over compensation for the impact, if any, of certain market factors, such as lack of liquidity. Hypothetical trading programs generally are also subject to the fact that they are designed with the benefit of hindsight. Hypothetical results also do not account for commissions or slippage.

The Company's simulations assume purchase and sale prices believed to be attainable. Yet traders are going to be getting into trades at different times and using various exit approaches, which may result in different pricing and outcomes. You may or may not receive the best available price on the purchase or the sale of a position in actual trading.

Information provided by the Company is not investment advice. The Company is not a registered investment adviser, stock broker, or brokerage. You agree that the Company does not represent, warrant, or take responsibility that any account will or is likely to achieve profit or losses similar to those shown. Examples published by the Company are selected for illustrative purposes only. They are not typical and do not represent the typical results of all stocks within the Company's software or its individual scans and searches. No independent party has audited any hypothetical performance contained at this Web site, nor has any independent party undertaken to confirm that they reflect the trading method under the assumptions or conditions specified.

Offers Disinterested Commentary and Analysis

The Company does not receive any form of payment or other compensation for publishing information, news, research, or any other material concerning specific securities on the Network that is intended to affect or influence the value of securities. The Company, and its personnel, do not engage in front-running of recommendations and do not trade against one's own recommendations.

The Company and its management may benefit from an increase or decrease in the share prices of the profiled companies, and/or may have other actual or potential conflicts of interest. If a particular security featured in a newsletter publication is concurrently owned by the Company in its corporate brokerage account, or in any of the individual accounts of the Company's principals or analysts / writers, that fact will be disclosed. The Company, its principals, analysts and writers may choose to purchase a security or derivative featured in one of its newsletter publications, but typically will wait three (3) trading days from the date of publication before initiating said purchase.

Disclaimers, Terms & Conditions | Privacy Policy

Copyright © 2019